Archive by Author

Stakeholder meeting October 29: Study of Health Outcomes in Children with ASD and Their Families

26 Oct

The United States National Institute of Mental Health has called a meeting to discuss a study on health outcomes on children with ASD and their families. The meeting will also be a chance for community input.

I don’t see an easy way to provide input in advance of the meeting.

There are many topics I can think of for input, but a big piece of information would be to question why this is limited to children with ASD?

Meeting Announcement

Study of Health Outcomes in Children with ASD and Their Families – Stakeholders’ Meeting

October 29, 2010
NIH Neuroscience Center
6001 Executive Blvd.
Conference Room C
Rockville, MD 20852

Sponsored by:

National Institute of Mental Health (NIMH)

NIMH recently awarded a two-year contract to The Lewin Group to conduct a study of health outcomes in children with autism spectrum disorders (ASD) and their families. The objective of this study is to advance our understanding of ASD, including variables related to diagnosis, health conditions, and health care outcomes, using existing administrative data.

NIMH will host an informational stakeholders’ meeting, inviting participation from individuals with ASD, parents of children with ASD, community care providers, ASD researchers, and patient advocates. The Health Outcomes research team will provide an overview of the goals, objectives, and methods of the study. The meeting is also a venue for input from the community about the particular health issues that are of the greatest concern, as well as ASD-specific challenges or complications related to health care service provision and utilization

The meeting will be open to the public, and will be held on October 29, 2010, 2:00pm to 4:00pm EDT at the NIH Neuroscience Center. Participation by webinar is also possible. To register for in-person attendance at the meeting, or for webinar participation, please go to: http://dgimeetings.cvent.com/d/ydq5rc/4W .

It seems likely that this study will address questions such as whether there is a higher incidence of gastrointestinal problems in autistics, and how GI issues evolve with time in those kids who have it. I would expect attention on questions such as whether autistic kids are more prone to infections and/or get more antibiotics, how medicated these kids are, the incidence of epilepsy, the incidence of apraxia, and how these conditions progress with time.

I hope a good method is made for input for this meeting, other than attendance.

A correction

23 Oct

A commenter noted a mistake I made in a recent post, Mental health problems in youths committed to juvenile institutions: prevalences and treatment needs. As noted in the post, I assumed that “coercive institutional care” was a term for criminal incarceration. This assumption was incorrect and I apologize for the error.

Reading Age of Autism Part 6 – everything old is new again

21 Oct

If I had to take a guess I’d say Part I of Age of Autism was written primarily by Dan Olmsted and (so far) Part II is written primarily by Mark Blaxill. Why? Well, Part I is well written bullshit with a decent narrative flow and is full of new (if wrong) ideas. Part II has so far regurgitated the Amish and Somali episodes and I’m in the middle right now of a really dragging account of how Andrew Wakefield got into the game during which I have actually groaned aloud twice and had to put down a few times and watch something more intelligent on TV – something like When Stunts Go Bad for example. A decent writer Mark Blaxill is not.

Part II is also very much more heavy on the out-and-out anti-vaccination rhetoric and if I want to give a dispassionate, honest review I’d have to say that the differences between Part’s I & II are more than glaringly obvious – they’re more obvious than a fluorescent painted whore in a Kansas Church. Its a shame really as I have a penchant for well put together bullshit and Part I was exactly that. Part II is badly constructed bullshit. Imagine a shanty town constructed next to St. Paul’s Cathedral and thats what Parts I & II of Age of Autism stand together like.

So everything old is new again, its like taking a trip back in time as we see Simon Murch et al get introduced and the concept of Crohn’s Disease being marketed as vaccine caused being touted around as a viable hypothesis (I’m not up to the MMR/autism thing yet).

Now don’t get me wrong I’ve nothing against a trip down memory lane but all the hallmarks of a bad writer and worse editing are here aplenty and its really not much fun reading about how Simon Murch is the leading etc etc. I’m sure he is – in fact I _know_ he is but I can’t help but imagine the uninvested reader would find this focussing on frankly dull fact as exactly that – dull.

So basically same old same old so far. I’m moving house soon and won’t have web access for a week (eek!) but I’ll be reading and note taking don’t you worry. To be continued.

IACC meeting tomorrow

20 Oct

The Interagency Autism Coordinating Committee (IACC) is holding a regular meeting tomorrow. The announcement is below.

The IACC creates the “Strategic Plan” which guides autism research efforts in the United States. Primarily, the Plan is for use by U.S. governmental groups, but there is input from major private sources of autism research funding as well.

The meeting will be webcast at http://videocast.nih.gov/, and a coference call listen-only line will be available at:

USA/Canada Phone Number: 888-577-8995
Access code: 1991506

The IACC had a “Request for Input” (RFI), a call for public comments. Those comments are online here.

Interagency Autism Coordinating Committee (IACC) Full Committee Meeting

Please join us for an IACC Full Committee meeting that will take place on Friday, October 22, 2010 from 10:00 a.m. to 5:30 p.m. ET in Bethesda, MD. Onsite registration will begin at 9:00a.m.

Agenda: Invited speakers will give presentations on various aspects of autism spectrum disorder research and services and the IACC will discuss plans for the annual update of the IACC Strategic Plan for Autism Spectrum Disorder Research. Speakers include: Dr. Alexa Posny, Dr. Richard Frank, Ms. Wendy Fournier, Ms. Lori McIlwain and Dr. Kevin Pelphrey. The full agenda is available online at: http://iacc.hhs.gov/events/.

Meeting location:
The National Institutes of NIH, Main Campus – Google map imageMap and Directions

The William H. Natcher Conference Center

45 Center Drive

Conference Rooms E1/E2
Bethesda, Maryland 20892

The meeting will be open to the public and pre-registration is recommended. Seating will be limited to the room capacity and seats will be on a first come, first served basis, with expedited check-in for those who are pre-registered.

The meeting will be remotely accessible by videocast (http://videocast.nih.gov/) and conference call. Members of the public who participate using the conference call phone number will be able to listen to the meeting, but will not be heard.

Conference Call Access
USA/Canada Phone Number: 888-577-8995
Access code: 1991506

Individuals who participate using this service and who need special assistance, such as captioning of the conference call or other reasonable accommodations, should submit a request to the contact person listed above at least seven days prior to the meeting. If you experience any technical problems with the conference call, please-mail IACCTechSupport@acclaroresearch.com.

Please visit the IACC Events page for the latest information about the meeting, including registration, remote access information, the agenda, public comment instructions and information about other upcoming IACC events.

Contact Person for this meeting is:

Ms. Lina Perez
Office of Autism Research Coordination
National Institute of Mental Health, NIH
6001 Executive Boulevard, NSC
Room 8185a
Rockville, MD 20852
Phone: 301-443-6040
E-mail: IACCpublicinquiries@mail.nih.gov

The agenda is online, and below.

Time Event
9:00 a.m. Onsite Registration Desk Opens
10:00 Call to Order and Opening Remarks

Thomas Insel, M.D.
Director
National Institute of Mental Health and Chair, IACC
10:10 Review and Approval of July 16, 2010 Minutes
10:15 Alexa Posny, Ph.D.
Assistant Secretary of Special Education and Rehabilitative Services
U.S. Department of Education
10:45 Wandering and Autism: The Need for Data and Resources

Wendy Fournier
President
National Autism Association

Lori McIIwain
Board Chair
National Autism Association
11:15 The CLASS Act

Richard Frank, Ph.D.
Deputy Assistant Secretary for Policy and Evaluation
Department of Health and Human Services
11:45 Neural Signatures of Autism

Kevin Pelphrey, Ph.D.
Harris Associate Professor of Child Psychiatry
Child Study Center and Child Neuroscience Lab, Yale University
12:15 p.m. Lunch
1:00 Public Comments
1:30 Meeting Update: NICHD Workshop “Disparities in the Identification of Children with Autism Spectrum Disorders,” August 19, 2010

Alice Kau, Ph.D.
Health Scientist Administrator
Intellectual and Developmental Disabilities Branch, Eunice Kennedy Shriver National Institute of Child Health and Human Development

Regina Smith James, M.D.
Director
Division of Special Populations, Eunice Kennedy Shriver National Institute of Child Health and Human Development
1:40 Meeting Update: NIEHS Workshop “Autism and the Environment: New Ideas for Advancing the Science,” September 8, 2010

David Armstrong, Ph.D.
Senior Investigator, Chief of the Laboratory of Neurobiology
National Institute of Environmental Health Sciences
1:50 Meeting Update: “Genetic Risk Factors for Autism Spectrum Disorders: Translating Genetic Discoveries into Diagnostics” Symposium, September 1-2, 2010

Stephen Scherer, Ph.D.
Director
The Centre for Applied Genomics, The Hospital for Sick Children
Director
McLaughlin Centre for Molecular Medicine, University of Toronto
2:00 Meeting Update: Simons Foundation Autism Research Initiative (SFARI) Annual Meeting, September 12-14, 2010

Gerald Fischbach, M.D.
Scientific Director
Simon’s Foundation Autism Research Initiative
2:10 Research Update: Study of Health Outcomes in Autistic Children and Their Families

Ann Wagner, Ph.D.
Chief
Neurobehavioral Mechanisms of Mental Disorders Branch, National Institute of Mental Health
2:20 Data Sharing Update: National Database for Autism Research (NDAR)

Michael Huerta, Ph.D.
Director
National Database for Autism Research, National Institute of Mental Health
2:25 Committee Business

* Workshop Update – Services Subcommittee

2:30 Break
2:45 Committee Business

* RFI update
* Portfolio Analysis update
* Discussion: Updating the Strategic Plan

5:00 Public Comments Discussion Period
5:30 Closing Comments and Adjournment

Recruitment of Wakefield’s study subjects…part 1

20 Oct

It has already been well established that Andrew Wakefield was employed by Dawbarns, a lawfirm working with families bringing forward claims of vaccine damage from MMR. Brian Deer made this clear in his investigative reporting starting in 2004.

Even with that, I must say I was surprised and dismayed to read it again and in much greater detail in the GMC transcripts.

Mr. Wakefield has asserted over the years that the children for the Lancet study came through “formal channels”. He denied the possibility of litigation bias in a letter to the Lancet.

Amongst the myriad questions left open is why did a group of parents of disabled children seek out Mr. Wakefield’s team when that team had no particular expertise in autism. Why did families from all over the U.K. and beyond seek out the Royal Free Hospital?

There is evidence elsewhere in the transcripts of Mr. Wakefield’s direct involvement with recruiting some children for his study, but here we can see how the law firm was actively recruiting children, and that Mr. Wakefield was aware of this.

For example, here is a section from the transcripts from day 3 of the hearings. This is where Ms. Smith was laying out the case against Mr. Wakefield before testimony was started.

Let’s first put the following letter into perspective on time. The letter is from August 1996. 1996 was two years before the Lancet paper was published. Earlier that year (in February) Mr. Wakefield had agreed to work as an expert in the MMR litigation. The Fall of 1996 was when the Lancet 12 children were seen at the Royal Free. After this initial group of children, more (over 70 total) children were seen at the Royal Free for suspected Gi complaints and regression.

Ms. Smith’s comments are in bold. The letter from Mr. Barr are blockquoted.

If I can just read through it, this is a letter to Dr Wakefield from Mr Barr, the solicitor for the claimants:

Dear Andy

I refer to the telephone message left … and I am writing to confirm that at long last the Legal Aid Board has now given authorisation for the pilot study. The limit is £55,00 which does include the setting up costs.

I think we need to have a meeting about the mechanics of running the study because obviously we both have different roles to play and we also need to make sure that the investigation is as effective as possible both from your point of view and ours.

As I mentioned on the telephone the only slight cloud is that the Legal Aid Board rather hoped that within the £55,000 you would be able to include preparing us a written over-view in relation to vaccine damage. We have discussed this and I don’t know whether it is impertinent to suggest that you should do it within that funding bracket.

We also need to make sure that cases are properly selected for the pilot study. Obviously only legally aided children can be included (we have details of cases where legal aid has either not been granted or has not been applied for). Again a meeting might help to sort those out. For all the cases that we have obtained legal aid we have already put in hand obtaining records. In many cases we already have the complete set.

I assume that for the purposes of the pilot study you would like us to supply a full set of medical records and as much information about the cases as you can get hold of.

Then there is reference to two of the vaccine support groups who were concerned about a forthcoming MMR campaign, and:

“When we meet I would like to discuss with you and perhaps engage in further correspondence with Dr Salisbury/The Committee on Safety of Medicines”,

and it then goes into some details and requests information about the vaccine trials.

That letter is followed on in terms of tracing the story through. That is in August 1996 and in September 1996 Dr Wakefield is referred to in another of the newsletters that I have already gone to, again produced by the solicitors in the MMR litigation and again sent to Mrs 12. That is at page 189.

There is so much in this letter of interest, but I will pull out one fact: Mr. Barr was sending newsletters out informing people about the work starting at the Royal Free, including “Mrs 12”, the mother of child 12 of the Lancet study.

There was certainly an effort to recruit children to Mr. Wakefield’s team, and Mr. Wakefield was aware of this.

Mr. Wakefield has asserted that none of the children in the Lancet study were involved in litigation at the time of that research. I do not know what criteria Mr. Wakefield uses for “involved in litigation”, but it is clear that at least one (and from other evidence it appears more like 4 or five) of the Lancet 12 were working with Mr. Barr and his lawfirm at Dawbarns at the time of the study.

Ms. Smith also discussed a September 1996 newsletter from Dawbarns. This was at the same time that Mr. Wakefield was applying for ethical approval for his study at the Royal Free. Here is a section of that newsletter:

Autism and inflammatory bowel disease

A substantial number of children referred to us are suffering from chronic stomach problems and/or have developed autism-like symptoms. Our own researches indicate that these two conditions may well have been caused by the MMR/MR vaccines and that they may well be linked.

We are trying to put together as much information as possible about the apparent link between these two conditions and the vaccines. If you have any information, or know of other families with children who have one or other of these conditions (or both) following vaccination we would be very interested to hear from you. If your child has the condition(s) and you have not yet received the fact sheet produced by Dr Andrew Wakefield, do contact us.”

It was no coincidence that the children reported in the 1998 Lancet paper claimed regression, GI complaints and many blamed the MMR vaccine.

Was there “litigation bias” and a strong measure of self-selection in the Lancet 12? Absolutely. Was Mr. Wakefield aware of this? Yes. Did he make this clear to the public, or even his own colleagues? No.

And we have yet to discuss what active role Andrew Wakefield himself took in recruiting study subjects to the Royal Free.

The Rouse letter: how Wakefield was almost caught in 1998

19 Oct

For those who have followed the story of Andrew Wakefield, the fact that he had multiple conflicts of interest is not news. The subjects in his now retracted 1998 paper in The Lancet were far from a random sample of autistics. They were even far from a random sample of autistics with GI problems. Brian Deer has made this very clear. The GMC ruled that it is clear that Andrew Wakefield was fully aware of the biased nature of these children.

But, Brian Deer was not the first to catch on. A letter to the Lancet in May 1998, a few short months after the now retracted Wakefield paper was published, a letter to the editor was published. It was by a Mr. Rouse, a public heath professional:

“Sir – After reading Andrew Wakefield and colleagues’ article I did a simple internet search and quickly found the Society for the Autistically Handicapped. I downloaded a 48 page fact sheet produced for the Society by Dawbarns, a firm of solicitors in King’s Lynn.

It seems likely then that some of the children investigated by Wakefield et al came to attention because of the activities of this Society and information from parents referred in this way would suffer from recall bias. It is a pity that Wakefield et al do not identify the manner in which the 12 children investigated were referred (e.g. from local GPs, self-referral via parents, or secondary/tertiary or international referral). Furthermore, if some children were referred directly or indirectly because of the activities of the Society for the Autistically Handicapped, Wakefield should have declared his co-operation with that organisation.”

It was so close to exposing the truth, but there would be another 6 years before Brian Deer would reopen the question and show that Andrew Wakefield did indeed have serious conflicts of interests (as well as many ethical failings) in the Lancet paper.

Mr. Rouse stressed the “Society for the Autistically Handicapped”, which Mr. Wakefield was able to claim no association with. Here, read the Wakefield response for yourself. The first two paragraphs refer to other letters to the Lancet, I am only showing the response to the Rouse letter:

A Rouse suggests that litigation bias might exist by virtue of information that he has downloaded from the Internet, from the Society for the Autistically Handicapped. Only one author (AJW) has agreed to help evaluate a small number of these children on behalf of the Legal Aid Board. These children have all been seen expressly on the basis that they were referred through the normal channels (eg, from general practitioner, child psychiatrist, or community paediatrician) on the merits of their symptoms. AJW had never heard of the Society for the Autistically Handicapped and no fact sheet has been provided for them to distribute to interested parties. The only fact sheet that we have produced is for general practitioners, which describes the background and protocol for investigation of children with autism and gastrointestinal symptoms. Finally all those children referred to us (including the 53 who have been investigated already and those on a waiting list that extends into 1999) have come through the formal channels described above. No conflict of interest exists.

Much discussion went into this exchange. There even appears to be two versions of the Rouse letter.

Mr. Wakefield argued that his response was factually correct. That he responded to some specific questions raised by the Rouse letter. I am reminded of the courtroom oath in the United States, that one must tell the truth, the whole truth and nothing but the truth. Mr. Wakefield seems to avoid “the whole truth” here and elsewhere.

Here is what the prosecution had to say about Mr. Wakefield’s response:

So even at that stage, we suggest that Dr Wakefield failed to set out in straightforward terms the nature of his involvement with the litigation and the receipt of funding, because he says he has never heard of the Society for the Autistically Handicapped – well, fair enough – but he does not state that he had heard of, and had been working for more than two years with, Dawbarns, who were the solicitors in the MMR litigation, as an expert for them. That is despite the fact that he is responding to an allegation which he himself understood to be alleging litigation bias.

Secondly, he says that he “has agreed to help evaluate a small number of these children on behalf of the Legal Aid Board”, but he makes no reference to the fact that they had funded his research to the tune of £25,000 at that stage, with more anticipated to come.

Dr Wakefield’s explanation for that, you will not be surprised to hear, is that he was responding to specific points only. It is our submission that it is a hallmark of his evidence that he falls back on this kind of terminological or grammatical analysis of allegations or questions which have been put to him in an attempt to obscure his own failure to respond openly and honestly and then he places the burden on others to pin him down and to ask for what he actually describes as “further and better particulars”. So he says that is what should be done if people want straightforward answers, in effect.

It is worth seeing how Mr. Wakefield’s colleagues thought of the Rouse letter. In summarizing the defense for Prof. Walker-Smith (one of the Wakefield team who was also sanctioned by the GMC), his attorney noted

(a) At the time that the Lancet children were investigated at the Royal Free, Professor Walker-Smith had no knowledge of Dr Wakefield’s dealings with the Legal Aid Board.

(b) Some time around the beginning of 1997, Professor Walker-Smith became aware that Dr Wakefield was acting as an expert on behalf of a number of children in a group action concerning MMR. Professor Walker-Smith did not want to have any involvement in actual or potential litigation.

(c) Professor Walker-Smith was not aware of the litigation status of the Lancet children at the time that the Lancet paper was written.

(d) It was not until the Rouse correspondence in the Lancet in 1998 that Professor Walker-Smith became aware that Dr Wakefield had agreed to “evaluate a small number of these children on behalf of the Legal Aid Board”. This was after the Lancet paper had been published.

(e) It was not until Mr Deer contacted him many years later that he was informed about a sum of money that had allegedly been paid to Dr Wakefield by the Legal Aid Board.

(f) It was not until 2004 that Professor Walker-Smith learned the number of Lancet children that were part of the “class action” in which Dr Wakefield was involved.

There is a lot in that statement of interest, but for this discussion I will focus on the statement that Mr. Wakefield did not disclose to his colleagues that some of the children he was working were involved with the Legal Aid Board. They learned about it from the Rouse letter. Why wasn’t Mr. Wakefield transparent even with his own colleagues?

Back to the Wakefield response, I think that it is a stretch to say that “no conflict of interest exists” or that the children came through formal channels. This ignores the fact that Mr. Wakefield played an active part in recruiting children into the study. This ignores the fact that Mr. Wakefield was aware that there indeed was a litigation bias involved in both himself and many of the study subjects.

As long as we are looking at the letters to the Lancet, here is one by Barbara Loe Fisher, of the self-named National Vaccine Information Center (in reference to a letter to the Lancet by members of the CDC):

“The pre-emptive strike by US vaccine policymakers on Andrew Wakefield and his colleagues’ investigation into the immunopathology of children with chronic enterocolitis and regressive developmental disorder brings into sharp relief the inappropriate intervention of politics into what should be an apolitical scientific examination.”

What is brought “into sharp relief” was that Mr. Wakefield’s study was not an “apolitical scientific examination”. Rather it was a litigation funded and driven project where crucial facts were hidden from the public. A true vaccine safety organization, which Ms. Fisher’s NVIC is not, would now be condemning Mr. Wakefield’s manipulation of the story. Instead, she gives him awards.

The Rouse letter shows that Mr. Wakefield failed in his duty to explain the details of his research to the public, and to his own colleagues. From where I sit, it also looks as though the Lancet failed to ask the direct questions that should have been raised at this point. They allowed Mr. Wakefield to avoid the sticky questions raised by the fact that Mr. Wakefield was involved in the MMR litigation.

Of course it is easy in hindsight to see the patterns. At the time, Mr. Wakefield was a highly respected researcher and much of what we now know was hidden. But it is very frustrating to think that the story could have been (should have been) exposed so quickly after the publication of the Lancet paper.

Is there a point to blogging Age of Autism – the book?

18 Oct

Recently Sully asked if there was value in continuing to report of a certain AJ Wakefield’s exploits. It got me to thinking – is there continuing value on blogging Age of Autism, the book?

The most recent chapters have descended into very very familiar territory with the Somali and Amish episodes being regurgitated to seemingly little or no point. Are LB/RB readers of the opinion that this sort of material requires review?

Don’t get me wrong, I would continue to blog about _new_ material in the book but as I have come to the section of the book where phrases like:

The obvious risk that immigrants to any Western country face is over-vaccination.

Page 250

are tossed around without any reason or evidence to back up the implication that ‘over’-vaccination is dangerous, or indeed there is such a things as ‘over-vaccination’, then I begin to question the worth of this material to LB/RB readers.

What do you think Dear Reader?

Safeminds defends treatments the FDA deemed “dangerously misleading”

18 Oct

The United States Food and Drug Administration (FDA) recently announced that they had sent warning letters to eight groups who were promoting chelation products without prescriptions and with unproven claims of efficacy.

Chelation is a mainstay of many alternative medical practitions, especially in autism. There is a hypothesis that autism is caused by mercury poisoning. Autism symptoms don’t look like mercury poisoning and multiple studies have been performed testing the hypothesis and shown no link. But the idea lives on. Autistics, mostly children, are subjected to chelation “therapy” to remove heavy metals from the body. After over a decade of this practice, there is still no demonstration that chelation does anything to help autistics. There are studies on Peruvian hamsters which are used to support the idea that autism is caused by mercury poisoning. No, seriously, one of the supports for the mercury/autism link is a study on Peruvian Hamsters. Just goes to show how tenuous the “science” backing chelation is.

Here is part of the FDA statement:

Federal regulators are warning eight companies to stop selling so called ‘chelation’ products that claim to treat a range of disorders from autism to Alzheimer’s disease.

The Food and Drug Administration (FDA) says the companies have not proven their products are safe and effective in treating autism spectrum disorder, cardiovascular disease, macular degeneration, Parkinson’s disease or any other serious illness. Some of the companies also claim their products can detect the presence of heavy metals in the body in an attempt to justify the need for chelation therapy.

One of the more vocal organizations promoting the mercury/autism “link” is a group called SafeMinds. So it isn’t a surprise that they would respond to the FDA warnings..

Here is the opening paragraph from the SafeMinds response:

The FDA issued a media release and held a press conference on over-the-counter chelating products. A recording of the press conference was made available this afternoon (recording available at 800-839-7073). FDA issued warning letters to 8 companies promoting over-the-counter nutritional supplements for chelation therapy (HERE). Chelation is a method of removing heavy metals from the body. The FDA warning has no bearing on prescription chelation drugs which are used under the supervision of medical professionals.

“Nutritional Supplements”? How does a chelator count as a “nutritional supplement”? The human body does not produce chemicals like DMSA which are used for chelation. SafeMinds is well aware of the falacy of the “nutritional supplement” argument after the recent debacle over the chelator turned “supplement” OSR, which had to be pulled from production.

So, SafeMinds starts downplaying the fact that chelators are drugs and, as such, should be regulated.

But they quickly change the tune and acknowledge that these are drugs: “The FDA warning has no bearing on prescription chelation drugs which are used under the supervision of medical professionals.”

As I read this, I had to ask myself “Why did SafeMinds chose such imprecise language?” Let me explain:

Assume a medical professional, say a chiropractor or a nutritionist, “supervises” my use of the prescription drug DMSA, but sells the drug to me without a prescription (as these professionals can not write prescriptions). That would fit into the SafeMinds interpretation, but is clearly not the intent of the FDA statement.

Here is an accurate statement: The FDA warning does not have bearing on the use of chelation drugs prescribed by and supervised by a medical professional.

Continuing with the SafeMinds statement:

In its press conference, the FDA implied that chelation products were being used by parents of children with autism without a doctor’s supervision, but on questioning by reporters, FDA representatives were unable to back up the claim with any evidence of use of OTC chelation products by autism parents or of their use without medical supervision. The FDA asserted that the OTC products being promoted were dangerous and could lead to kidney damage, dehydration and death. On questioning by reporters, the FDA admitted that it had received no reports of adverse reactions to the products or to chelation in general, other than 1 death 5 years ago which was due to a medical error and in which a prescription drug was used.

Note that SafeMinds chose their words carefully. They don’t state that the practice doesn’t occur. SafeMinds just states that the FDA didn’t have the evidence on hand of the “use of OTC chelation products by autism parents or of their use without medical supervision.”

Is Safeminds so out of touch with the online autism community that they can’t find groups promoting over-the-counter (OTC) chelators by autism families? The practice is common. Surely SafeMinds members peruse the exhibitor booths at the parent-conventions (like Autism One).

Google search: “how to buy DMSA without a prescription”. Lot’s of hits.

Here is hit #2: dmsachelation.com/autism/. Pretty clear they are targeting autism treatment there, just from the URL. The blurb on Google for this site? “This page IS intended to show you where to buy DMSA without a prescription. You can get DMSA prescribed, however the cost will range from $2-3 per pill. …”

I didn’t capitalize “IS” in that statement, they did. They wanted to emphasize that one could buy chelators without a prescription.

SafeMinds states that the FDA has received no reports of adverse events from chelation in general. I find this odd. The FDA must not follow online autism parent groups such as those on Yahoo. The FDA must not have read transcripts of the Omnibus Autism Proceeding, which included a description of a child who regressed after being given chelation therapy (under the watchful eye of a prominent alt-med doctor). The FDA must not have performed a google search on chelation deaths with site set to CDC.gov.

First hit, “Deaths Associated with Hypocalcemia from Chelation Therapy — Texas, Pennsylvania, and Oregon, 2003–2005“.

When it comes to the question of “why” adverse events are not commonly reported I am again reminded of the OSR fiasco. The company that sold OSR specifically told their clientele to contact the company in case of adverse reactions. No mention was made of contacting the FDA (which can be done here). I guess I could search the websites of the groups that promote OTC chelators to see if they inform their clients of the ability to report their drug/supplements to the FDA. Somehow I feel confident that I would be able to find groups (possibly many or most) do not give that information.

SafeMinds posted their statement on the blog they sponsor, The Age of Autism. Another sponsor of that blog is Lee Silsby, a compounding pharmacy. They list chelators such as DMSA and EDTA under the category “autism treatments” (Specialties | Autism Treatments | Transdermal DMSA Cream, or Specialties | Autism Treatments | EDTA (calcium)). Not under “heavy metal poisoning” treatments, autism treatments.

The Autism Research Institute, a group which promotes much in the way of alternative medicine as therapies for autism, has a chart that is often used to promote chelation. In their survey, they claimed that over 70% of parents reported that their child got better with chelation. The survey has been often criticized as being unscientific and very biased. Even with this biased sample, 3% of parents reported that their child “got worse” with chelation.

A couple side notes are worth mentioning. First, in that survey the ARI list chelation under “Biomedical/Non-Drug/Supplements”. Non drug? Supplement? I doubt the FDA will agree. Second, the ARI survey lists secretin therapy as beneficial for autism. Secretin hit the news in the 1990’s as a potential autism therapy and has since been shown to be no more effective than a placebo. The survey is very, very biased towards “biomedical” treatments.

Surely SafeMinds is aware of this survey. As in, definitely they are aware of it. Just as Safeminds are certainly aware of the child in the Omnibus proceeding who suffered after chelation. But SafeMinds pretend as though there are no adverse reactions. It is disingenuous, to say the least.

SafeMinds ends their statement with this paragraph:

SafeMinds agrees with the FDA that products being promoted as drugs and biologics should have thorough and unbiased assessments for safety and that parents should work with their healthcare professionals when considering health interventions. SafeMinds feels that FDA has tried to cast autism parents in a negative light without any supporting evidence, by implying that autism parents were giving their children dangerous products without medical oversight. Only on questioning by the media did the FDA have to back off from its wild claims. SafeMinds feels the FDA owes the autism community an apology.

Basically, SafeMinds have taken the Human Shield defense. Rather than actually discuss the facts, SafeMinds attacks the FDA for “wild claims” and claims that the FDA owes the autism community an apology.

From the perspective of this autism parent I would say, yes, the FDA owes us an apology: for taking so damned long to address this issue. The abuse of chelation as a “treatment” for autism has been going on for many years. It is about time that the FDA cracked down and made the “wild claim” that a prescription drug should be given by perscription.

Heck, the FDA isn’t even making the “wild claim” that toxicology treatments should be performed by toxicologists. Just someone with a prescription pad.

Why isn’t SafeMinds telling autism families to seek out medical toxicologists to test and treat heavy metal poisoning? The answer is painfully clear. The methods of diagnosis and treatment that groups like SafeMinds promote do not compare to the methods used by those trained specifically to treat heavy metal intoxication.

Should make one pause to wonder.

Mental health problems in youths committed to juvenile institutions: prevalences and treatment needs

17 Oct

I read the following abstract with much dismay:
(note, a comment below notes that I made a mistake, a large mistake, in assuming that “coercive institutional care” was a term for criminal incarceration. I apologize for the error)

Mental health problems in youths committed to juvenile institutions: prevalences and treatment needs.

Ståhlberg O, Anckarsäter H, Nilsson T.

Forensic Psychiatry, University of Lund, Lund, Sweden, ola.stahlberg@neuro.gu.se.
Abstract

Many international studies show that adolescents in coercive institutional care display high prevalences of mental disorders, especially in the form of disruptive behavior disorders [including attention-deficit/hyperactivity disorder (AD/HD), oppositional defiant disorder, and conduct disorder], anxiety disorders, and mood disorders. High degrees of overlap across mental disorders have also been reported. In addition, institutionalized adolescents are often traumatized. Despite this well-documented psychiatric morbidity, the mental health care needs of detained adolescents are often overlooked. The main objective of this study is to assess prevalences of psychiatric disorders, results of intelligence tests, and previous contacts with child and adolescent psychiatric services among adolescents in institutional care. DSM-IV diagnoses, mental health contacts, substance abuse, neurocognitive abilities, and school performance were registered in 100 adolescents (92 boys, 8 girls) aged 12-19 years (mean age 16.0; SD ± 1.5) consecutively committed to Swedish juvenile institutions between 2004 and 2007. At least one psychiatric disorder was diagnosed in 73% of the subjects: 48% met DSM-IV diagnostic criteria for AD/HD, 17% for an autism spectrum disorder, and 10% for a mental retardation. The collapsed prevalence for psychiatric disorders requiring specialist attention was 63%. Our data indicate that systematic diagnostic procedures are crucial in the treatment planning for institutionalized adolescents. Adequate treatment strategies need to be designed and implemented to meet the extensive mental health care needs of this vulnerable population.

I admit, I don’t have the paper. I am assuming “coercive institutional care” means juvenile jail. 73% of those in such care had at least one psychiatric disorder. 17% were autistic. 10% had intellectual disability.

So many questions come up. The authors note the need to identify conditions and provide appropriate treatment. One also must ask if the high percentage of people with these conditions means that (a) there is a high percentage of perpetrators who have these conditions and/or (b) is there a higher conviction rate for people with these conditions.

I know I’m not phrasing this well, but this really bugs me.

Autism anti-vaccine doctor banned for a year

17 Oct

Dr Sarah Myhill is a 52 year old GP from Powys. She has been banned for a year whilst the GMC investigate claims she might pose a “risk to patients”.

The panel is satisfied that, based on the complaints made, and the concerns raised, there is sufficient information before it to indicate that there may be impairment of your fitness to practise and that such impairment may pose a real risk to patients”

Full story:

A GP has been suspended from practising medicine for a year by the General Medical Council (GMC).

Dr Sarah Myhill, 52, who has a private practice near Knighton, Powys had claimed she was a “pioneer” in the treatment of chronic fatigue syndrome.

The GMC imposed an interim ban while it investigates her claims, but it said Dr Myhill might pose a “risk to patients”.

She was banned from prescribing drugs for 18 months by the GMC in April, and told to take down part of her website.

It came after a group of GPs based in Yorkshire claimed she had provided “inappropriate” treatment to a patient in June 2009.

Dr Myhill recommended vitamin and magnesium injections for suspected chronic fatigue syndrome, a treatment an expert said had “no clinical or biochemical basis”.

Stuart Jones, a senior clinical scientist at Queen’s Hospital in Romford, Essex, also raised concerns about advice on the doctor’s website concerning breast cancer screening and child vaccinations.

The website discouraged women from using the oral contraceptive pill, recommended an alternative method of breast cancer screening and restated the link between the measles, mumps and rubella jab and autism, which has now been discredited.

The latest GMC hearing heard that there were “repeated and significant concerns raised by former patients, medical practitioners and other members of the public”.

GMC panel chair Dr Peter Maguire said: “The circumstances which bring patients to your practice by their very nature make your patients vulnerable, notwithstanding any actual health issues.

“The panel is satisfied that, based on the complaints made, and the concerns raised, there is sufficient information before it to indicate that there may be impairment of your fitness to practise and that such impairment may pose a real risk to patients.

‘The panel has been extremely concerned by your possible lack of understanding of the requirements of modern day best practice, as well as a seeming lack of perception and understanding of the consequences of your actions.”

Dr Myhill tried to challenge the interim conditions at the review hearing, which was held in public at her request.

It was attended by around a dozen of her supporters.

The hearing also heard that the GMC had received further complaints since April’s ruling.

They included a suggestion that Dr Myhill had attempted to exploit a loophole in a requirement she take down information on her website by posting a link to an “ungagged” version of the site.

Dr Myhill said she could not be held responsible if other people had chosen to copy her website.

Her 12-month interim order will be reviewed within three months.

Dr Myhill has been asked to comment.